Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

Published:2024-06 Issue:6 Volume:23 Page:588-602
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Cree Bruce A C,Kim Ho Jin,Weinshenker Brian G,Pittock Sean J,Wingerchuk Dean M,Fujihara Kazuo,Paul Friedemann,Cutter Gary R,Marignier Romain,Green Ari J,Aktas Orhan,Hartung Hans-Peter,She Dewei,Rees William,Smith Michael,Cimbora Daniel,Katz Eliezer,Bennett Jeffrey L

Funder

Horizon Therapeutics plc

Publisher

Elsevier BV

Reference30 articles.

1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders;Wingerchuk;Neurology,2015

2. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders;Akaishi;Sci Rep,2020

3. B lymphocytes in neuromyelitis optica;Bennett;Neurol Neuroimmunol Neuroinflamm,2015

4. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica;Bennett;Ann Neurol,2009

5. Molecular level characterization of circulating aquaporin-4 antibodies in neuromyelitis optica spectrum disorder;Li;Neurol Neuroimmunol Neuroinflamm,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting B cells in neuromyelitis optica spectrum disorder;The Lancet Neurology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP